PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.34%
Positive EBIT growth while AXSM is negative. John Neff might see a substantial edge in operational management.
30.35%
Positive operating income growth while AXSM is negative. John Neff might view this as a competitive edge in operations.
30.26%
Positive net income growth while AXSM is negative. John Neff might see a big relative performance advantage.
30.58%
Positive EPS growth while AXSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
33.88%
Positive diluted EPS growth while AXSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.94%
Share count expansion well above AXSM's 0.91%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
5.92%
Diluted share count expanding well above AXSM's 0.91%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
10.50%
Positive OCF growth while AXSM is negative. John Neff would see this as a clear operational advantage vs. the competitor.
10.43%
Positive FCF growth while AXSM is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10668.67%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
79.98%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
60.25%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-3178.86%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
82.89%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
76.87%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
496.60%
Positive growth while AXSM is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
159.22%
Positive 5Y equity/share CAGR while AXSM is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-89.45%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.48%
Negative asset growth while AXSM invests at 396.29%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-43.72%
We have a declining book value while AXSM shows 2496.02%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
14.13%
Debt growth far above AXSM's 0.90%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-30.15%
Our R&D shrinks while AXSM invests at 21.28%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-30.87%
We cut SG&A while AXSM invests at 67.85%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.